Results 311 to 320 of about 11,282,122 (391)
Objective Autoimmune rheumatic diseases commonly affect individuals of childbearing age, with historically increased adverse pregnancy outcomes in this group. The advent of disease‐modifying antirheumatic drugs (DMARDs) has fostered more suitable conditions for pregnancy; however, this is accompanied by challenges in ensuring safe use in reproductive ...
Athena Chin+4 more
wiley +1 more source
Objective Cognitive impairment (CI) is common in patients with systemic lupus erythematosus (SLE). Despite its prevalence, the immune mechanisms are not well understood. We previously reported elevated serum levels of S100A8/A9 and matrix metalloproteinase 9 (MMP‐9) in patients with SLE and CI.
Carolina Muñoz‐Grajales+18 more
wiley +1 more source
Objective Lupus low disease activity state (LLDAS) is a validated treatment target in systemic lupus erythematosus (SLE) but limited studies have explored the role of LLDAS in lupus nephritis (LN). This study aims to investigate the frequency and predictors of LLDAS attainment, and its benefit on LN relapse and renal function preservation in patients ...
Chak Kwan Cheung+6 more
wiley +1 more source
Targeted proteomic analysis identifies ACVRL1 as a marker of cerebral edema in aneurysmal subarachnoid hemorrhage. [PDF]
Yang BSK+11 more
europepmc +1 more source
Hydroxychloroquine Associated with Lower Glomerular Filtration Rate Decline in Lupus Nephritis
Background Hydroxychloroquine (HCQ) protects kidney function in lupus nephritis (LN) by preventing flares, yet some cohort studies show no significant benefit in kidney function with HCQ. Clarifying these conflicting findings by showing early and long‐term benefits of HCQ on kidney function preservation is critical. Therefore, we analyzed data from our
Shivani Garg+9 more
wiley +1 more source
Biocompatibility in hemodialysis: artificial membrane and human blood interactions. [PDF]
Ávila E+3 more
europepmc +1 more source
Background While treat‐to‐target urate‐lowering therapy (ULT) is endorsed as best practice in gout management, limited data exist on its impact on health‐related quality of life (HRQoL). We assessed the impact of treat‐to‐target ULT on HRQoL among participants receiving protocolized gout care, identifying factors associated with HRQoL and HRQoL change.
Austin Barry+16 more
wiley +1 more source
Next-generation leukemia diagnostics: Integrating LC-MS/MS proteomics with liquid biopsy platforms. [PDF]
Singh V.
europepmc +1 more source
Diurnal rhythm of the human plasma proteome. [PDF]
S Jóhönnuson EM+8 more
europepmc +1 more source
Plasma proteomic signatures of dual cognitive and mobility decline in older adults. [PDF]
Tian Q+4 more
europepmc +1 more source